Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Three-Arm Study of ME-401 Monotherapy in Subjects With Relapsed/Refractory CLL, SLL, or FL, of ME-401 in Combination With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination With Zanubrutinib in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL

NCT02914938 is registered in ClinicalTrials.gov with MEI Pharma, Inc. as lead sponsor.

NCT NCT02914938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02914938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Three-Arm Study of ME-401 Monotherapy in Subjects With Relapsed/Refractory CLL, SLL, or FL, of ME-401 in Combination With Rituximab in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL, and of ME-401 in Combination With Zanubrutinib in Subjects With Relapsed/Refractory CLL/SLL or B-cell NHL
Lead sponsor
MEI Pharma, Inc.
Phase
Phase 1
Overall status
Terminated
Start date
October 31, 2016
Completion date
March 29, 2023
Enrollment
97 (actual)
Sites
24

Conditions

As the registry lists them; a condition with its own page is linked.

chronic lymphocytic leukemia (cll), diffuse large b-cell lymphoma (dlbcl), follicular lymphoma (fl), high grade non-hodgkin's lymphoma, mantle cell lymphoma (mcl), marginal zone b cell lymphoma, small lymphocytic lymphoma (sll)